Regulatory approval of a novel artificial intelligence-based tool that provides precise measurement of retinal fluid may introduce major paradigm changes in the monitoring of patients with neovascular age-related macular degeneration.
βIt is a precision management tool, a VEGF meter, which is what Philip Rosenfeld was asking for when anti-VEGF therapies started. More precisely, it is a fluid meter and is now ready for use in clinical practice,β Ursula Schmidt-Erfurth, MD, PhD, told Healio/OSN.
As a tool that every eye specialist can introduce in their daily routine practice, the
Uncategorized